ATE177535T1 - Identifizierung von liganden durch selektive vermehrung von, durch rezeptoren tranzfizierten zellen - Google Patents

Identifizierung von liganden durch selektive vermehrung von, durch rezeptoren tranzfizierten zellen

Info

Publication number
ATE177535T1
ATE177535T1 AT94923478T AT94923478T ATE177535T1 AT E177535 T1 ATE177535 T1 AT E177535T1 AT 94923478 T AT94923478 T AT 94923478T AT 94923478 T AT94923478 T AT 94923478T AT E177535 T1 ATE177535 T1 AT E177535T1
Authority
AT
Austria
Prior art keywords
ligands
receptors
trancefied
propification
selective
Prior art date
Application number
AT94923478T
Other languages
English (en)
Inventor
Mark Robert Brann
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of ATE177535T1 publication Critical patent/ATE177535T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • C12Q2334/10—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases p-Nitrophenol derivatives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT94923478T 1993-07-13 1994-07-13 Identifizierung von liganden durch selektive vermehrung von, durch rezeptoren tranzfizierten zellen ATE177535T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9169493A 1993-07-13 1993-07-13

Publications (1)

Publication Number Publication Date
ATE177535T1 true ATE177535T1 (de) 1999-03-15

Family

ID=22229179

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94923478T ATE177535T1 (de) 1993-07-13 1994-07-13 Identifizierung von liganden durch selektive vermehrung von, durch rezeptoren tranzfizierten zellen

Country Status (13)

Country Link
US (3) US5707798A (de)
EP (1) EP0708922B1 (de)
JP (1) JP3102571B2 (de)
KR (1) KR100272459B1 (de)
AT (1) ATE177535T1 (de)
AU (1) AU679253B2 (de)
CA (1) CA2167048C (de)
DE (1) DE69417037T2 (de)
DK (1) DK0708922T3 (de)
ES (1) ES2129658T3 (de)
IL (1) IL110298A (de)
NZ (1) NZ269442A (de)
WO (1) WO1995002823A1 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69527585T2 (de) * 1994-06-08 2003-04-03 Affymetrix, Inc. Verfahren und Vorrichtung zum Verpacken von Chips
US6287850B1 (en) * 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5977121A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Use of moxonidine for the treatment of atherosclerosis
ATE293699T1 (de) * 1995-03-03 2005-05-15 Syngenta Participations Ag Kontrolle der pflanzengenexpression durch rezeptor-vermittelte transaktivation in gegenwart von einem chemischen ligand
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
WO1997013864A1 (en) 1995-10-10 1997-04-17 Novartis Ag Juvenile hormone or one of its agonists as a chemical ligand to control gene expression in plants by receptor mediated transactivation
JP2001504321A (ja) * 1996-06-17 2001-04-03 マイクロサイド・ファーマシューティカルズ・インコーポレーテッド 微生物菌株プールを用いるスクリーニング方法
US5985584A (en) * 1997-02-19 1999-11-16 American Cyanamid Company Method to identify plant proteins that function in G protein coupled systems and compositions therefor
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
EP0887081B1 (de) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Humäne Serumglucocorticoidregulierte Kinase, ein Ziel für chronischer Nierenerkrankung und diabetische Nephropathie
EP1069917A4 (de) * 1998-03-20 2005-02-09 Genzyme Corp Neue komplementierende rezeptor-liganden paare und adoptive immunotherapie die diese verwendet
JP2002510790A (ja) * 1998-04-06 2002-04-09 ブンセン ラッシュ ラボラトリーズ インコーポレーテッド 指向的進化バイオセンサ
US6277588B1 (en) * 1998-05-01 2001-08-21 Tel Aviv University Screening of cell populations
WO2000035274A1 (en) * 1998-12-17 2000-06-22 The Johns Hopkins University School Of Medicine Olfactory receptor expression libraries and methods of making and using them
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
US6589738B1 (en) 1999-11-09 2003-07-08 Elitra Pharmaceuticals, Inc. Genes essential for microbial proliferation and antisense thereto
AU3263101A (en) * 1999-11-24 2001-06-04 Millennium Pharmaceuticals, Inc. Expression cloning method
US6521414B2 (en) * 2000-02-01 2003-02-18 Agy Therapeutics, Inc. Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1
US20030092071A1 (en) * 2000-02-01 2003-05-15 Jasna Jerecic Interaction of NMDA receptor with protein tyrosine phosphatase
EP1254954A4 (de) * 2000-02-08 2004-06-16 Ssp Co Ltd Verfahren zur erkennung von liganden oder liganden ähnlichen niedermolekularen verbindungen
RU2002126554A (ru) * 2000-03-06 2004-03-20 Акадиа Фармасьютикалз, Инк. (Us) Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
GB2360282A (en) * 2000-03-17 2001-09-19 Bioinvent Int Ab Making and using micro-arrays of biological materials
AR028385A1 (es) * 2000-04-28 2003-05-07 Acadia Pharm Inc Agonistas muscarinicos
CN1333213A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——细胞信号传导蛋白My D24.09和编码这种多肽的多核苷酸
US6576422B1 (en) 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
US6977152B2 (en) * 2001-09-07 2005-12-20 Virtual Arrays, Inc. Biological assays using coded RNA reporters
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
BR0213611A (pt) * 2001-10-02 2005-12-20 Acadia Pharm Inc Composto, composição farmacêutica, seus usos, método para aumentar a atividade de um receptor colinérgico, métodos para tratamento ou prevenção de distúrbio mental, dor, pressão intraocular aumentada e progressão ou formação de placas amilóides
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
ES2251624T3 (es) * 2001-12-28 2006-05-01 Acadia Pharmaceuticals Inc. Analogos de la tetrahidroquinolina como los agonistas muscarinicos.
WO2003057698A2 (en) * 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Spiroazacyclic compounds as monoamine receptor modulators
AU2003228285A1 (en) * 2002-03-05 2003-09-22 Virtual Arrays, Inc. Multiplexed analysis of cellular responses using endogenous reporter genes
US7199844B2 (en) * 2002-05-28 2007-04-03 Rfstream Corporation Quadratic nyquist slope filter
WO2003104216A1 (en) * 2002-06-10 2003-12-18 Acadia Pharmaceuticals Inc. Urotensin ii receptor modulators
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
CN100509804C (zh) * 2002-06-24 2009-07-08 阿卡蒂亚药品公司 N-取代哌啶衍生物作为血清素受体试剂
DE10233516A1 (de) 2002-07-23 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Identifizierung von Substanzen
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6884473B2 (en) * 2002-12-24 2005-04-26 Macronix International Co., Ltd. Method for fabricating metal silicide
PT1587789E (pt) 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
JP2006515628A (ja) 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
EP1638946A2 (de) * 2003-02-19 2006-03-29 Acadia Pharmaceuticals Inc. 2-aminoethyl substituierte pyrimidin-2-one, cyclopropane, pyrazoline, pirimidine und benzothiazepine und ihre verwendung als urotensin ii und somatostatin 5 rezeptor liganden
NZ542690A (en) * 2003-03-28 2009-04-30 Acadia Pharm Inc Muscarinic M1 receptor agonists for pain management
US20070196865A1 (en) * 2003-09-16 2007-08-23 Molecular Devices Corporation Methods Of Screening Compositions For G Protein-Coupled Receptors Aganist Agonists
KR20060088885A (ko) * 2003-09-25 2006-08-07 아카디아 파마슈티칼스 인코포레이티드 뉴로펩티드 ｆｆ 리셉터 2의 작용제를 이용한 신경병증성통증 치료 방법
NZ546580A (en) * 2003-11-03 2009-06-26 Acadia Pharm Inc High throughput functional assay for G-protein coupled receptors using a rap-ras chimeric protein
PT1696931E (pt) 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
BRPI0509524A (pt) * 2004-04-01 2007-09-18 Acadia Pharm Inc formas cristalinas de n-desmetilclozapina
US7825265B2 (en) * 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
US20070004679A1 (en) * 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
EP1756101A2 (de) * 2004-05-17 2007-02-28 Acadia Pharmaceuticals Inc. Androgenrezeptormodulatoren und verfahren zur krankheitsbehandlung damit
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
JP4996467B2 (ja) * 2004-09-27 2012-08-08 アカディア ファーマシューティカルズ インコーポレイテッド Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成
US20060134670A1 (en) * 2004-11-19 2006-06-22 Fabrice Piu Enabling tools to identify ligands for hormone nuclear receptors
CN101119993B (zh) 2005-01-10 2015-03-04 阿卡蒂亚药品公司 作为选择性雄激素受体调节剂的氨基苯基衍生物
US20080318960A1 (en) * 2005-05-26 2008-12-25 Ethan Burstein PAR2-modulating compounds and their use
US20070123508A1 (en) * 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
EP1937614A1 (de) * 2005-10-17 2008-07-02 Arcadia Pharmaceuticals Inc. Eisenkatalysierte kreuzkopplungsreaktionen von imidoylderivaten
WO2007047737A1 (en) * 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2007079239A2 (en) * 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
US7655396B1 (en) 2006-09-29 2010-02-02 Allergan, Inc. Methods for detecting receptor modulator activity
EP2120962A1 (de) 2006-12-18 2009-11-25 Allergan, Inc. Verfahren und zusammensetzungen zur behandlung von gastrointestinalen erkrankungen
HRP20130713T1 (en) 2007-03-19 2013-09-30 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
EP2288345B1 (de) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psychopharmazeutika
EP2291181B9 (de) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine zur Behandlung von depressionartigen Symptomen
US20120196302A1 (en) * 2008-10-07 2012-08-02 Lai Lee Jene Detecting method
WO2010111353A1 (en) 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US20110150769A1 (en) * 2009-08-06 2011-06-23 Anderson David J Identification and use of compounds for treating persistent pain
EP2493910A1 (de) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Makrozyklische ghrelin-rezeptorantagonisten und gegenagonisten sowie verwendungsverfahren dafür
US20140241990A1 (en) * 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
AU2014240139A1 (en) 2013-03-15 2015-09-17 Acadia Pharmaceuticals Inc. Muscarinic agonists
CA2937107C (en) 2014-01-17 2020-12-22 Cornell University Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
PL3325444T3 (pl) 2015-07-20 2021-12-06 Acadia Pharmaceuticals Inc. Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3442940A1 (de) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterierte ketaminderivate
EP3558311A1 (de) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose
EP3612210A4 (de) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System Manipulierte antigenrezeptoren exprimierende immunzellen
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019040104A2 (en) 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
WO2019040105A2 (en) 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
SG11202001062XA (en) 2017-08-21 2020-03-30 Acadia Pharm Inc Compounds, salts thereof and methods for treatment of diseases
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
EP3806839B1 (de) 2018-06-14 2024-08-07 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Agonist des retinsäure-rezeptors beta2 mit kardioprotektiven effekten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5462856A (en) * 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
DK0548165T3 (da) * 1990-09-13 2001-07-16 Univ Duke Ekspression af G-proteinkoblede receptorer i gær
EP0745121B1 (de) * 1992-05-14 2007-06-20 Baylor College Of Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie

Also Published As

Publication number Publication date
EP0708922A1 (de) 1996-05-01
EP0708922B1 (de) 1999-03-10
DE69417037D1 (de) 1999-04-15
US5955281A (en) 1999-09-21
CA2167048C (en) 2001-09-25
NZ269442A (en) 1997-06-24
KR100272459B1 (ko) 2000-11-15
AU7333094A (en) 1995-02-13
JP3102571B2 (ja) 2000-10-23
IL110298A (en) 1999-04-11
DE69417037T2 (de) 1999-10-21
AU679253B2 (en) 1997-06-26
US5707798A (en) 1998-01-13
CA2167048A1 (en) 1995-01-26
JPH09500023A (ja) 1997-01-07
ES2129658T3 (es) 1999-06-16
DK0708922T3 (da) 1999-09-27
WO1995002823A1 (en) 1995-01-26
IL110298A0 (en) 1994-10-21
US5912132A (en) 1999-06-15

Similar Documents

Publication Publication Date Title
ATE177535T1 (de) Identifizierung von liganden durch selektive vermehrung von, durch rezeptoren tranzfizierten zellen
ATE386814T1 (de) Gemischte g-proteinzusammensetzung und ihre verwendung
EP0873361A4 (de) Kernrezeptor-Liganden und Liganden bindenden Domänen
DE69329318D1 (de) Immunotestverfahren unter Verwendung von Mikropartikel enthaltenden, unterschiedlichen, nachweisbaren Substanzen
DE69022286D1 (de) Reagenzien, Verfahren und Testsätze zum Nachweis von Amphetaminen durch einen Fluoreszenz-Polarisations-Immunoassay.
DE69004943D1 (de) Vorrichtung zum Reformieren von Kohlenwasserstoffen.
DK1000345T3 (da) Fremgangsmåde og apparat til dannelse af referencer for fluorescensintensitetssignaler
DE68901632D1 (de) Reaktionsgefaess zur durchfuehrung von aufeinanderfolgenden analytischen testen.
DE3582740D1 (de) Spezifischer bindungstest unter verwendung von anti-g6pdh als markierungsmittel.
DE69333726T8 (de) Glucagonrezeptoren
AT375367B (de) Verfahren zur herstellung von als histamin h2-rezeptor-antagonisten wirkenden nitroverbindungen
ATE324462T1 (de) Assays zur detektierung von modulatoren der cytoskeletalen funktion
ATE172541T1 (de) Verfahren zum nachweis biologischer wechselwirkungen, insbesondere in rezeptorbindungs-assays
ATE178410T1 (de) Verfahren zur hochempfindlichen dosierung von herztroponin - i
DE69928250D1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
DE60022661D1 (de) Raman analysesystem zur olefinpolymerisationskontrolle
DE3575604D1 (de) Vorrichtung zum nachweis von metallischen abriebteilchen.
IT8222205A1 (it) Procedimento per fare granuli contenenti urea come componente principale
DE69019231D1 (de) Vorrichtung zum Messen der Konzentration von NOx.
DE3580538D1 (de) Monoklonaler antikoerper, verfahren zu seiner herstellung, den monoklonalen antikoerper enthaltendes reagenz zum nachweiss eines krebsantigens und verfahren zu seiner herstellung.
ATE11202T1 (de) Schneidgeraet zum abhaeuten von schlachttieren.
DE69002511D1 (de) Neue thiophosphorverbindungen, verfahren zu ihrer herstellung und ihre verwendung als schmiermittelzusatzstoffe.
DE3481202D1 (de) Verfahren zur analyse der taetigkeit von rezeptoren bestimmter zellen.
DE3583626D1 (de) Teststueck zum nachweis von nitrit.
DE3381569D1 (de) Reagenz zum nachweis von cholinesterase.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties